Lilly Asia Ventures has returned for a $147m series D round that will allow InventisBio to advance its treatments for breast cancer and gout into phase 2 clinical trials.

China-based oncology and metabolic drug developer InventisBio yesterday revealed $147m in series D funding from investors including Lilly Asia Ventures, a regional corporate venturing subsidiary of pharmaceutical firm Eli Lilly.

GL Ventures, an affiliate of private equity firm Hillhouse Capital, led the round, which also featured Qiming Venture Partners, Janchor, AIHC Capital, Matrix Partner China, Dyee Capital, E Fund Capital, OrbiMed Asia, Pudong Innotek, Advantech Capital and CMB International.

The round also included unnamed participants.

InventisBio is working on a…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn